Receive our newsletter – data, insights and analysis delivered to you
June 29, 2009

BiovaxID Now Available In Europe

BiovaxID, a therapeutic anti-cancer vaccine produced by Biovest, a subsidiary of Accentia Biopharmaceuticals, is now available in Europe. BiovaxID is a personalised vaccine, which uses the patient's own immune system to treat follicular non-Hodgkin's lymphoma and potentially other B-cel

By cms admin

BiovaxID, a therapeutic anti-cancer vaccine produced by Biovest, a subsidiary of Accentia Biopharmaceuticals, is now available in Europe.

BiovaxID is a personalised vaccine, which uses the patient’s own immune system to treat follicular non-Hodgkin’s lymphoma and potentially other B-cell blood cancers, such as chronic lymphocytic leukaemia, mantle cell lymphoma and multiple myeloma.

University of Cologne Professor of Medicine Volker Diehl said that Phase III results, although positive, did not include a BiovaxID maintenance regimen consisting of periodic booster shots.

“This booster regimen may be key in continuing to stimulate a robust and enduring immune response, thus further improving results, and perhaps even resulting in durable remissions for some patients,” Diehl said.

Biovest is planning to include multiple booster vaccines for potential maintenance therapy purposes, as part of the vaccine delivery for prescriptions processed under the named-patient programme.

The treatment will be available on a named-patient basis where physicians are permitted to supply investigational drugs to willing patients who qualify for the treatment.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU